CooperBiomedical therapeutic div.
Executive Summary
Exploring possibility of licensing to third parties the development, manufacture and sale of its therapeutic division's R&D projects and products as well as the sale of the therapeutic division's remaining operating units. Total fiscal 1984 R&D costs of $2.3 mil. were allocated to: alpha-1 antitrypsin, for the treatment of respiratory diseases; development of a liposome aerosol delivery system; refinement of human cell-produced viral inhibitors; and investigation of an immune system stimulator for use as an anticancer therapeutic.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.